You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

SHINGRIX overview

SHINGRIX is a vaccine used in adults 50 years of age and older to protect against shingles (herpes zoster) and post-herpetic neuralgia (long-lasting nerve pain following shingles).

It can also be used in adults 18 years of age and older who are at increased risk of herpes zoster.

The vaccination schedule consists of two doses: an initial dose, followed by a second dose 2 months later. If flexibility in the vaccination schedule is necessary, the second dose can be administered between 2 and 6 months after the first dose. Based on your medical condition, your doctor may also recommend that you receive the second injection 1 month after the first injection.

For further information please consult the Patient information leaflet (PIL).

- This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any side effects not listed in the Patient information leaflet.

You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store.

By reporting side effects you can help provide more information on the safety of this medicine.

SHINGRIX is a registered trademark of the GlaxoSmithKline group of companies.